Compare BOSC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | TVRD |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 12 |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 27.5M |
| IPO Year | 2002 | N/A |
| Metric | BOSC | TVRD |
|---|---|---|
| Price | $4.42 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $29.50 |
| AVG Volume (30 Days) | 23.3K | ★ 1.2M |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $1.50 |
| 52 Week High | $6.72 | $43.65 |
| Indicator | BOSC | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 35.58 |
| Support Level | $4.50 | $1.50 |
| Resistance Level | $4.58 | $4.32 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 64.58 | 3.65 |
BOS Better Online Solutions Ltd is a provider of comprehensive solutions to enterprises, comprised of services, equipment, and custom-made automatic machines. The company manages its business in three reportable divisions: the Supply Chain Solutions Division, the RFID Division, and the Intelligent Robotics Division. The majority of revenue derives from Supply Chain Solutions, which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their component-supply needs. Its geographic areas are Israel, East Asia, India, America, Europe, and the rest of the world. Geographically company derives the majority of its revenue from Israel.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.